In a 12-patient multiple myeloma pilot study, researchers demonstrated that anti-CD3 and anti-CD20 bispecific antibody (CD20Bi) activated both cellular and humoral anti-myeloma immunity that was detectable after patients received an autologous stem cell transplant.
In a 12-patient multiple myeloma pilot study, researchers demonstrated that anti-CD3 and anti-CD20 bispecific antibody (CD20Bi) activated both cellular and humoral anti-myeloma immunity that was detectable after patients received an autologous stem cell transplant. The results were presented by Lawrence Lum, MD, of the Karmanos Cancer Institute in Detroit, at the 2013 American Society of Hematology Annual Meeting and Exposition, held in New Orleans. Here, Dr. Lum discusses the study results and the implications for combining immunotherapy with stem cell transplant in multiple myeloma patients.
Reference: Lum L, Thakur A, Al-Kadhimi Z, et al. Induction of anti-myeloma cellular and humoral immunity by pre-targeting clonogenic myeloma cells prior to stem cell transplant with T cells armed with anti-CD3 × anti-CD20 bispecific antibody leads to transfer of cellular and humoral anti-myeloma immunity. ASH Annual Meeting Abstracts. 2013; Abstract 139.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.